Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma.
Posterior segment
Retinoblastoma
Toxicity
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
30
07
2018
accepted:
10
09
2018
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
The presence of a posterior vitreous detachment (PVD) may play a role in the development of severe retinal toxicity following intravitreal melphalan (IVM) injection for vitreous seeding. We aimed to evaluate the incidence of PVD in retinoblastoma eyes and its association with retinal toxicity after IVM. We reviewed 112 eyes of 81 retinoblastoma patients with B-scan images available for review from 2010 to 2017. A cohort with vitreous seeding treated with IVM was compared to a cohort that did not undergo injection. The primary outcome measure was the presence of PVD at diagnosis and after treatment. Secondary measures included IVM-associated retinal toxicity and other ocular complications. The incidence of PVD was 20% at diagnosis, and in eyes with B-scans available both at diagnosis and after treatment 18% of eyes developed a PVD over the course of therapy, more frequently after IVM ( In this cohort of patients, there did not appear to be an association with the presence of PVD during IVM and the development of retinal toxicity.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
The presence of a posterior vitreous detachment (PVD) may play a role in the development of severe retinal toxicity following intravitreal melphalan (IVM) injection for vitreous seeding. We aimed to evaluate the incidence of PVD in retinoblastoma eyes and its association with retinal toxicity after IVM.
METHODS
METHODS
We reviewed 112 eyes of 81 retinoblastoma patients with B-scan images available for review from 2010 to 2017. A cohort with vitreous seeding treated with IVM was compared to a cohort that did not undergo injection. The primary outcome measure was the presence of PVD at diagnosis and after treatment. Secondary measures included IVM-associated retinal toxicity and other ocular complications.
RESULTS
RESULTS
The incidence of PVD was 20% at diagnosis, and in eyes with B-scans available both at diagnosis and after treatment 18% of eyes developed a PVD over the course of therapy, more frequently after IVM (
CONCLUSION
CONCLUSIONS
In this cohort of patients, there did not appear to be an association with the presence of PVD during IVM and the development of retinal toxicity.
Identifiants
pubmed: 31367584
doi: 10.1159/000493687
pii: oop-0005-0238
pmc: PMC6615322
doi:
Types de publication
Journal Article
Langues
eng
Pagination
238-244Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Br J Ophthalmol. 2012 Aug;96(8):1084-7
pubmed: 22368262
Br J Ophthalmol. 2012 Aug;96(8):1078-83
pubmed: 22694968
Pediatr Blood Cancer. 2013 Apr;60(4):688-93
pubmed: 22997170
Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1691-5
pubmed: 23381655
Br J Ophthalmol. 2013 Oct;97(10):1231-6
pubmed: 23740960
Br J Ophthalmol. 2014 Mar;98(3):292-7
pubmed: 24187047
Saudi J Ophthalmol. 2013 Jul;27(3):147-50
pubmed: 24227979
JAMA Ophthalmol. 2014 Mar;132(3):319-25
pubmed: 24407202
Ophthalmology. 2014 Sep;121(9):1810-7
pubmed: 24819859
Ophthalmic Genet. 2014 Dec;35(4):193-207
pubmed: 25321846
J Pediatr Ophthalmol Strabismus. 2014 Dec 12;51 Online:e92-4
pubmed: 25490242
Ophthalmology. 2015 Jun;122(6):1173-9
pubmed: 25795478
Indian J Ophthalmol. 2015 Feb;63(2):141-5
pubmed: 25827545
JAMA Ophthalmol. 2015 Dec;133(12):1459-63
pubmed: 26378741
Retina. 2016 Jun;36(6):1184-90
pubmed: 26630319
J Ocul Pharmacol Ther. 2016 May;32(4):230-5
pubmed: 26785130
Ocul Oncol Pathol. 2015 Feb;1(2):103-10
pubmed: 27172253
Ocul Oncol Pathol. 2015 Dec;2(2):105-11
pubmed: 27172535
Ophthalmology. 2017 Apr;124(4):488-495
pubmed: 28089679
Ocul Oncol Pathol. 2017 Jan;3(1):34-40
pubmed: 28275601
Ophthalmology. 2017 Dec;124(12):1817-1825
pubmed: 28655537
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29218818